<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This Schedule contains summary financial information extracted from the
Financial Statements of Progenics Pharmaceuticals, Inc. at June 30, 2000
and is qualified in its entirety by reference to such Financial
Statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                      13,050,095
<SECURITIES>                                51,839,790
<RECEIVABLES>                                2,631,800
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            54,512,411
<PP&E>                                       3,693,687
<DEPRECIATION>                               2,441,201
<TOTAL-ASSETS>                              69,134,474
<CURRENT-LIABILITIES>                        1,990,569
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        15,800
<OTHER-SE>                                  66,706,192
<TOTAL-LIABILITY-AND-EQUITY>                69,134,474
<SALES>                                              0
<TOTAL-REVENUES>                             6,725,746
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             9,545,064
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              47,389
<INCOME-PRETAX>                             (2,866,707)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (2,866,707)
<EPS-BASIC>                                    (0.24)
<EPS-DILUTED>                                    (0.24)


</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission